REG - N4 Pharma PLC - Work Programme Update

N4 PharmaAnnouncement

15/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220715:nRSO5599Sa&default-theme=true

RNS Number : 5599S  N4 Pharma PLC  15 July 2022

 

15 July 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Work Programme Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce a further update on its recent pre-clinical study with TNF
alpha.

 

On 13 June 2022 the Company provided an update that the Medicines Discovery
Catapult study showed clear tumour suppression with 10ug of the TNF-alpha
loaded onto Nuvec® which was a lower dose than used in the earlier studies.

Biochemical analysis of blood and tissue samples has now been completed.
Testing confirmed that treatment with 10ug TNF-alpha loaded onto Nuvec®
resulted in an increase in circulating plasma TNF-alpha levels.

 

Analysis also indicated that tissues including the liver and the tumour cells
may have been responsible for the transfection with the TNF plasmid and
subsequent release of TNF-alpha into the circulation to suppress the tumour.
 

 

This study provides further data to better understand the mechanism that
produced the tumour suppression. This data indicates the most appropriate use
of Nuvec® in the oncology field will likely be to combine it with one or more
nucleic acids alongside a targeting ligand to allow specific cancer cells to
be targeted.

 

The posters resulting from the original oncology studies undertaken by
Nanomerics have been presented at the CRS Annual Meeting in Montreal, Canada
and are available to view on the Company's website.

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We continue to make good progress in understanding how Nuvec® can be used in
the oncology space and this work, combined with the potential opening up of
the siRNA market and the early data coming from UQ on their oral work, gives
us a lot of material to further focus our route to commercial success.

 

"We will provide a further update of this along with our interim results."

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 which has been incorporated into UK law by the European
Union (Withdrawal) Act 2018.

 

Enquiries:

 

 N4 Pharma Plc                                       Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                      Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 IFC Advisory Limited                                Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQZLFFLDLFBBZ